company background image
CELU

Celularity NasdaqCM:CELU Stock Report

Last Price

US$1.69

Market Cap

US$245.1m

7D

3.7%

1Y

-68.8%

Updated

05 Dec, 2022

Data

Company Financials +
CELU fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

CELU Stock Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases.

Celularity Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celularity
Historical stock prices
Current Share PriceUS$1.69
52 Week HighUS$13.19
52 Week LowUS$1.35
Beta0.21
1 Month Change-24.22%
3 Month Change-41.52%
1 Year Change-68.82%
3 Year Change-83.00%
5 Year Changen/a
Change since IPO-82.76%

Recent News & Updates

Recent updates

News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Dec 14
News Flash: Analysts Just Made A Massive Upgrade To Their Celularity Inc. (NASDAQ:CELU) Forecasts

Shareholder Returns

CELUUS BiotechsUS Market
7D3.7%4.2%1.5%
1Y-68.8%-7.4%-14.9%

Return vs Industry: CELU underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: CELU underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is CELU's price volatile compared to industry and market?
CELU volatility
CELU Average Weekly Movement14.8%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: CELU is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: CELU's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016225Bob Haririhttps://www.celularity.com

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company’s lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn’s disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.

Celularity Inc. Fundamentals Summary

How do Celularity's earnings and revenue compare to its market cap?
CELU fundamental statistics
Market CapUS$245.07m
Earnings (TTM)-US$14.28m
Revenue (TTM)US$18.70m

13.1x

P/S Ratio

-17.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CELU income statement (TTM)
RevenueUS$18.70m
Cost of RevenueUS$19.08m
Gross Profit-US$376.00k
Other ExpensesUS$13.91m
Earnings-US$14.28m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.098
Gross Margin-2.01%
Net Profit Margin-76.37%
Debt/Equity Ratio23.9%

How did CELU perform over the long term?

See historical performance and comparison